Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Perhaps the greatest piece of investment wisdom ever...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by InitiumMMXXIIIon Dec 07, 2023 12:07am
114 Views
Post# 35772376

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Perhaps the greatest piece of investment wisdom ever...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Perhaps the greatest piece of investment wisdom ever...Lol. I did so much for the Bioasis market that I'm accused of victimizing people, even though I pointed out the downside, the issues, the problems. And the best part of it is, when you say I think I'm smarter than everybody, it's because you know I'm smart, informed and damn careful. No brag. Just a fact. Go ahead. Have some fun with that. Please continue with that accusation.

I'm moving ahead with my plans.

About the Cancun guy? Maybe you oughta think about that. What was that all about. Was that a little pawn in just the right place? An obvious stupid move that maybe wasn't? You won't get it, but I may explain it one day.

Doesn't make any difference. The history needs telling and I haven't told a fraction of it yet. Journals, call logs, emails, text messages, none of it covered by Bioasis NDAs.

And this, all so that you can keep telling me I'm bankrupt, and you wouldn't know that unless I had told everybody. 

You can't embarrass me. You can't frighten me. The bankruptcy is almost over and it was a godsend. Something that's important to remember is that I have no loyalty to anybody who lies to me or to the shareholders. I have a long list of those.

Am I crazy? I don't know, not likely. Sure would help though.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities